Seeking Alpha 13 April 15
Obviously, the Celgene announcement was very good news for Mesoblast, and there are three obvious reasons for the share price increase.
Firstly, it provides a US vehicle (if Celgene takes up the first right of refusal on the project) for its most advanced program, JR-031 for treating acute GVHD (filed for approval in Japan).
Secondly, a group of other Mesoblast programs are included in the first right of refusal, so this is a potential opportunity to fast track other programs.
Thirdly, on the corporate front, Celgene's interest might put some pressure on TEVA (NYSE:TEVA), which has close to a 20% stake in Mesoblast through its acquisition of Cephalon. TEVA also has a major partnership with Mesoblast on chronic heart disease, with phase 3 trials in progress.
For full report see
http://seekingalpha.com/article/306...559813c8533d86478967cc5e7642d50&uprof=45&dr=1
- Forums
- ASX - By Stock
- MSB
- Further thoughts on Celgene deal
Further thoughts on Celgene deal, page-5
-
- There are more pages in this discussion • 79 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add MSB (ASX) to my watchlist
|
|||||
Last
$1.11 |
Change
0.010(0.91%) |
Mkt cap ! $1.261B |
Open | High | Low | Value | Volume |
$1.09 | $1.11 | $1.07 | $4.794M | 4.399M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 14500 | $1.10 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.11 | 141676 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 14500 | 1.100 |
2 | 93112 | 1.095 |
2 | 37684 | 1.090 |
3 | 40400 | 1.085 |
2 | 61100 | 1.080 |
Price($) | Vol. | No. |
---|---|---|
1.110 | 141676 | 5 |
1.115 | 41050 | 3 |
1.120 | 157964 | 9 |
1.125 | 61233 | 3 |
1.130 | 111595 | 5 |
Last trade - 16.10pm 11/07/2024 (20 minute delay) ? |
Featured News
MSB (ASX) Chart |